Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GH Guardant Health Inc.

Post-Mkt 05-21 19:21:32 EDT

118.01

+3.04

+2.64%

盘后117.91

-0.10-0.08%

18:49 EDT

High121.01	Low111.20	Vol4.93M
Open113.44	D1 Closing114.97	Amplitude8.53%
Mkt Cap15.64B	Tradable Cap14.99B	Total Shares132.57M
T/O581.67M	T/O Rate3.89%	Tradable Shares127.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GH","market":"US","secType":"STK","nameCN":"Guardant Health Inc.","latestPrice":118.01,"timestamp":1779393600000,"preClose":114.97,"halted":0,"volume":4934165,"hourTrading":{"tag":"盘后","latestPrice":117.91,"preClose":118.01,"latestTime":"18:49 EDT","volume":894889,"amount":105602214.061104,"timestamp":1779403785897,"change":-0.1,"changeRate":-0.000847,"amplitude":0.020168},"delay":0,"changeRate":0.026441680438375283,"floatShares":127000000,"shares":132573424,"eps":-3.404949,"marketStatus":"Post-Mkt","change":3.04,"latestTime":"05-21 19:21:32 EDT","open":113.44,"high":121.01,"low":111.2,"amount":581672897.8511751,"amplitude":0.085327,"askPrice":118.01,"askSize":18,"bidPrice":116.4,"bidSize":25,"shortable":3,"etf":0,"ttmEps":-3.404949,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1779408000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":114.97,"preHourTrading":{"tag":"盘前","latestPrice":113.66,"preClose":114.97,"latestTime":"09:27 EDT","volume":3346,"amount":381098.5255,"timestamp":1779370038656,"change":-1.31,"changeRate":-0.011394,"amplitude":0.027659},"postHourTrading":{"tag":"盘后","latestPrice":117.91,"preClose":118.01,"latestTime":"18:49 EDT","volume":894889,"amount":105602214.061104,"timestamp":1779403785897,"change":-0.1,"changeRate":-0.000847,"amplitude":0.020168},"volumeRatio":2.396894,"impliedVol":0.5697,"impliedVolPercentile":0.243},"requestUrl":"/m/hq/s/GH/tweets","defaultTab":"tweets","newsList":[{"id":"1148294637","title":"Movement Alert｜Guardant Health Rises 5.01% in Regular Trading, Liquid Biopsy Test Receives FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1148294637","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148294637?lang=en_us&edition=fundamental","pubTime":"2026-05-21 23:29","pubTimestamp":1779377377,"startTime":"0","endTime":"0","summary":"On May 21, Guardant Health rose 5.01% in regular trading, trading at $120.65/share, with trading volume of $106 million. The rally was driven by the announcement that the U.S. Food and Drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637862333","title":"GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637862333","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637862333?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:37","pubTimestamp":1779363424,"startTime":"0","endTime":"0","summary":"GH Research ( ($GHRS) ) has provided an announcement. GH Research PLC will showcase new Phase 2b data on its inhaled psychedelic-based depression t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gh-research-to-present-new-gh001-phase-2b-data-in-treatment-resistant-depression-at-ascp-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gh-research-to-present-new-gh001-phase-2b-data-in-treatment-resistant-depression-at-ascp-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH","BK4196","BK4535","BK4551","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637908821","title":"Analysts Offer Insights on Healthcare Companies: Guardant Health (GH) and OS Therapies Incorporated (OSTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637908821","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637908821?lang=en_us&edition=fundamental","pubTime":"2026-05-21 00:40","pubTimestamp":1779295209,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Guardant Health (GH) and OS Therapies Incorporated (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-guardant-health-gh-and-os-therapies-incorporated-ostx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-guardant-health-gh-and-os-therapies-incorporated-ostx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4196","HCSG","XBI","BK4139","BK4585","LU0128526141.USD","BK4551","BK4535","GH","BK4581","BK4588","LU0029874061.USD","OSTX","XLV","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188757147","title":"Movement Alert｜Guardant Health Rises 10.09% in Regular Trading, FDA Approves Next-Generation Liquid Biopsy Test","url":"https://stock-news.laohu8.com/highlight/detail?id=1188757147","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188757147?lang=en_us&edition=fundamental","pubTime":"2026-05-21 00:16","pubTimestamp":1779293777,"startTime":"0","endTime":"0","summary":"On May 20, Guardant Health rose 10.09% in regular trading, trading at $108.18/share, with trading volume of $146 million. The surge was driven by the U.S. Food and Drug Administration approving the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636844976","title":"FDA approves Guardant360 Liquid CDx test for Guardant Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2636844976","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636844976?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:05","pubTimestamp":1779278749,"startTime":"0","endTime":"0","summary":"FDA clearance granted for Guardant Health’s Guardant360 Liquid CDx, a next-generation liquid biopsy for advanced cancer.The test expands the panel’s genomic footprint by 100x versus the prior Guardant360 CDx.Seven existing FDA-approved companion diagnostic indications for Guardant360 CDx transfer to the new assay.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL8yHv5z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4551","BK4535","GH","BK4196","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636675844","title":"FDA Approves New Guardant360 Liquid Cdx, the Largest FDA-Approved Liquid Biopsy Panel With a 100X Expanded Footprint","url":"https://stock-news.laohu8.com/highlight/detail?id=2636675844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636675844?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:05","pubTimestamp":1779278700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUA1CXCGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","BK4551","GH","BK4535","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636867791","title":"Judge sanctions law firm Quinn Emanuel, citing ethical lapses","url":"https://stock-news.laohu8.com/highlight/detail?id=2636867791","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636867791?lang=en_us&edition=fundamental","pubTime":"2026-05-20 06:09","pubTimestamp":1779228548,"startTime":"0","endTime":"0","summary":"Judge sanctions law firm Quinn Emanuel, citing ethical lapsesQuinn Emanuel says lawyers, firm apologize to courtMember of firm leadership to address conduct in visits to officesBy Mike Scarcella. Law firm Keller Postman appeals sanctions in Tylenol injury cases","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nL6N41W1BU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","BK4585","LU2065170008.USD","LU2324357040.USD","GH","LU0053671581.USD","LU1064131342.USD","BK4535","BK4196","LU0345770993.USD","LU2065731478.USD","LU0963586101.USD","LU0345770308.USD","LU0106261612.USD","LU2264538146.SGD","BK4139","BK4588","LU0012050646.USD","BK4551","LU2065171402.SGD","NTRA","LU2065169927.USD","LU1988902786.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636867781","title":"Guardant Health director Tariq Musa disposes of USD 11,131.36 in shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2636867781","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636867781?lang=en_us&edition=fundamental","pubTime":"2026-05-20 06:03","pubTimestamp":1779228190,"startTime":"0","endTime":"0","summary":"Guardant Health director Tariq Musa sold 116 common shares on May 18 at USD 95.96.Holdings fell to 8,662 shares following the sale.The filing also reported the vesting of 250 restricted stock units into 250 common shares on May 15 at USD 0.Derivative holdings were reported at 2,499 restricted stock units after the vesting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL3NX41z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health director Tariq Musa disposes of USD 11,131.36 in shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4585","BK4535","BK4196","GH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636783022","title":"GH Research Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2636783022","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636783022?lang=en_us&edition=fundamental","pubTime":"2026-05-19 18:42","pubTimestamp":1779187320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GHRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 19, 2026 06:42 ET (10:42 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009022","title":"Guardant Health grants 143,898 RSUs to 267 new employees under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009022","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009022?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:51","pubTimestamp":1779137478,"startTime":"0","endTime":"0","summary":"Guardant Health set inducement restricted stock unit grants covering 143,898 common shares for 267 new non-executive hires, with a May 11, 2026 grant date.The awards were issued under the company’s 2023 Employment Inducement Incentive Award Plan.One-third of each RSU vests each year on the anniversary of the vesting commencement date, subject to continued employment on each vesting date.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLbpnpCc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4588","BK4551","BK4585","GH","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009029","title":"Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009029?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:51","pubTimestamp":1779137460,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA3F5SVK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4535","BK4551","BK4588","BK4585","BK4196","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636002395","title":"Phase 2b JAMA Data and New Financing Tools Could Be A Game Changer For GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636002395","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636002395?lang=en_us&edition=fundamental","pubTime":"2026-05-18 15:31","pubTimestamp":1779089511,"startTime":"0","endTime":"0","summary":"GH Research PLC recently reported a wider Q1 2026 net loss of US$18.97 million while advancing GH001 for treatment-resistant depression, including publishing positive Phase 2b data in JAMA Psychiatry and completing key Phase 1 studies.\nAn interesting aspect of this update is how the company has paired clinical progress with expanded financing flexibility, adding a US$200 million at-the-market facility and a US$400 million universal shelf to support its late-stage development plans.\nWith this...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/phase-2b-jama-data-and-new-financing-tools-could-be-a-game-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ghrs/gh-research/news/phase-2b-jama-data-and-new-financing-tools-could-be-a-game-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4551","BK4196","GH","BK4007","BK4585","BK4535","BK4539","AIPO","GHRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635511320","title":"Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), GH Research (GHRS) and Doximity (DOCS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635511320","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635511320?lang=en_us&edition=fundamental","pubTime":"2026-05-16 09:51","pubTimestamp":1778896283,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA), GH Research (GHRS) and Do...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oruka-therapeutics-orka-gh-research-ghrs-and-doximity-docs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oruka-therapeutics-orka-gh-research-ghrs-and-doximity-docs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","HCSG","GH","BK4137","BK4581","ORKA","GHRS","BK4007","BK4551","BK4139","BK4535","DOCS","XLV","LABU","XBI","BK4539","BK4613","LU0128526141.USD","BK4585","BK4196","BK4167","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635035358","title":"These Analysts Revise Their Forecasts On GH Research After Q1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635035358","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635035358?lang=en_us&edition=fundamental","pubTime":"2026-05-15 22:58","pubTimestamp":1778857103,"startTime":"0","endTime":"0","summary":"GH Research (NASDAQ:GHRS) reported a larger loss than expected in Q1. Analysts lowered price targets, stock fell 3.4%. CEO noted progress in GH001 program.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/05/52601688/these-analysts-revise-their-forecasts-on-gh-research-after-q1-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","BK4196","BK4585","GH","BK4539","BK4551","BK4535","GHRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635038566","title":"GH Research price target raised to $35 from $25 at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2635038566","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635038566?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:46","pubTimestamp":1778852798,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald raised the firm’s price target on GH Research (GHRS) to $35 from $25 and keeps an Overweight rating on the shares. GH Research is...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gh-research-price-target-raised-to-35-from-25-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gh-research-price-target-raised-to-35-from-25-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635886082","title":"GH Research Is Maintained at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2635886082","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635886082?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:30","pubTimestamp":1778848200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GHRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 08:30 ET (12:30 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635845000","title":"GH Research Is Maintained at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2635845000","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635845000?lang=en_us&edition=fundamental","pubTime":"2026-05-15 20:14","pubTimestamp":1778847240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GHRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 08:14 ET (12:14 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635860010","title":"Canaccord Genuity Keeps Their Buy Rating on GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635860010","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635860010?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:12","pubTimestamp":1778843537,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on GH Research today and set a price target of $39.00. Kulkarni covers the Health...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-keeps-their-buy-rating-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-keeps-their-buy-rating-on-gh-research-ghrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH","GHRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635572700","title":"GH Research price target lowered to $39 from $42 at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2635572700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635572700?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:40","pubTimestamp":1778838042,"startTime":"0","endTime":"0","summary":"Citizens analyst Jason Butler lowered the firm’s price target on GH Research (GHRS) to $39 from $42 and keeps an Outperform rating on the shares. G...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gh-research-price-target-lowered-to-39-from-42-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gh-research-price-target-lowered-to-39-from-42-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635721199","title":"GH Research Launches $200 Million At-the-Market Share Offering With Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2635721199","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635721199?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:32","pubTimestamp":1778794376,"startTime":"0","endTime":"0","summary":"An announcement from GH Research ( ($GHRS) ) is now available. On May 14, 2026, GH Research PLC entered into an at-the-market equity offering sales...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gh-research-launches-200-million-at-the-market-share-offering-with-stifel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gh-research-launches-200-million-at-the-market-share-offering-with-stifel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4551","BK4196","GH","BK4127","SF","BK4585","BK4535"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.guardanthealth.com","stockEarnings":[{"period":"1week","weight":0.1676},{"period":"1month","weight":0.2624},{"period":"3month","weight":0.0807},{"period":"6month","weight":0.0906},{"period":"1year","weight":1.8764},{"period":"ytd","weight":0.1256}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.0459},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.2503},{"period":"ytd","weight":0.087}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.071093},{"month":2,"riseRate":0.25,"avgChangeRate":0.034152},{"month":3,"riseRate":0.5,"avgChangeRate":-0.022808},{"month":4,"riseRate":0.375,"avgChangeRate":-0.022604},{"month":5,"riseRate":0.625,"avgChangeRate":0.097313},{"month":6,"riseRate":0.714286,"avgChangeRate":0.081894},{"month":7,"riseRate":0.714286,"avgChangeRate":0.051469},{"month":8,"riseRate":0.571429,"avgChangeRate":0.08346},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065825},{"month":10,"riseRate":0.285714,"avgChangeRate":0.030366},{"month":11,"riseRate":0.75,"avgChangeRate":0.130427},{"month":12,"riseRate":0.5,"avgChangeRate":-0.066498}],"exchange":"NASDAQ","name":"Guardant Health Inc.","nameEN":"Guardant Health Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Guardant Health Inc.,GH,Guardant Health Inc.股票,Guardant Health Inc.股票老虎,Guardant Health Inc.股票老虎国际,Guardant Health Inc.行情,Guardant Health Inc.股票行情,Guardant Health Inc.股价,Guardant Health Inc.股市,Guardant Health Inc.股票价格,Guardant Health Inc.股票交易,Guardant Health Inc.股票购买,Guardant Health Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}